In Simple Terms
A new study suggests that regular drinking may make some cancer treatments work less well by changing the immune cells around a tumor. In experiments with mice, alcohol weakened the effect of treatment; patient records also linked drinking with shorter survival, especially in lung cancer. The patient data show a connection, though they cannot prove alcohol caused it.
How Alcohol Might Affect Cancer Treatment
Alcohol’s effects on cancer treatment may go beyond its general impact on health. A new study suggests it can change the balance of immune cells in and around a tumor, potentially weakening the response to a widely used kind of immunotherapy. Researchers combined experiments in mouse models of lung and bladder cancer with a retrospective analysis of records from patients treated with immune checkpoint inhibitors. The findings point to a possible biological pathway worth investigating, not a ready-made treatment strategy or definitive proof that drinking affects every patient.
What Does Anti-PD-1 Treatment Do?
Immune checkpoint inhibitors help the immune system attack cancer. Some of these treatments are antibodies that target a protein called PD-1, part of a regulatory system that limits the activity of certain immune cells. Tumors can exploit these brakes to reduce the chance of being attacked. Blocking them with medication may restore some immune cells’ ability to respond. Still, not all patients benefit equally, and complete responses to treatment remain relatively uncommon.
The study matters because treatment outcomes depend not only on the drug, but also on the state of the immune cells in and around a tumor. These cells are not all alike: some may help attack the tumor, while others may limit the response or perform different functions. Changes in their numbers or signaling can therefore alter the environment in which a treatment works. Researchers at the University of North Carolina at Chapel Hill set out to test this idea in the context of alcohol use.
The question also sits within a broader context. Alcohol use is common among people receiving cancer treatment, while its effects on adaptive immunity—the immune response driven by specialized cells that recognize particular targets—remain an area in need of closer study. Previous research has suggested that as many as 76.4% of people with cancer continue to drink alcohol. Medical organizations have called for more research into how drinking may relate to treatment outcomes. A clearer picture could help researchers understand factors that accompany treatment, without assuming that alcohol affects every patient in the same way.
Testing the Idea in Mouse Models of Cancer
In the experimental part of the study, researchers exposed mice with lung or bladder tumors to what they described as moderate-to-high levels of alcohol while treating them with antibodies targeting PD-1. In both models, the immunotherapy was about 50% less effective when ethanol was present, and tumors were more likely to return. These findings give researchers a basis for investigating whether changes in the tumor’s immune environment explain some of the reduced response. But they come from animal models and do not directly establish cause and effect in people.
The researchers looked beyond tumor size and its visible response to treatment. They examined immune cells that had entered the tumor tissue, focusing on T cells, which play central roles in recognizing and responding to infected or abnormal cells. In the MB49 bladder cancer model, ethanol was associated with fewer T cells inside the tumor. That decrease matters because it may mean that fewer of the immune cells the treatment relies on are present at the site of the disease.
The researchers also observed a shift in tumor-associated CD4+ cells. These cells moved toward an immune-helper pattern known as Th17, at the expense of the Th1 pattern. This does not mean that one pattern is always beneficial and the other harmful. Rather, the shift suggests that alcohol exposure was associated not only with a general drop in cell numbers, but also with a change in the dominant types of immune signals inside the tumor. The researchers suggest that this shift may be part of a broader picture in which the tumor environment becomes less supportive of a treatment response.
Changes in Tissue-Resident T Cells and Immune Brakes
Another change involved a decrease in tissue-resident T cells. These immune cells remain in a particular tissue rather than constantly circulating, and they can be on hand where a response is needed. The analysis also found a higher proportion of T cells carrying TIGIT, a receptor that acts as an alternative immune checkpoint. In the mouse model, then, ethanol exposure coincided with changes in several components: fewer T cells inside the tumor, a reduction in a group of tissue-resident memory cells, and an increase in cells expressing another inhibitory signal.
These details help explain why it is not enough to say that alcohol simply weakens the immune system. The study describes specific changes in the place where the tumor grows, including shifts in the types of cells and signals that may shape how they interact. The team also observed increased activity in fat-related signaling pathways controlled by SREBP in tumor-associated T cells. SREBP helps regulate how cells handle fats. Its importance here is that its activity changed alongside the reduced treatment effect, prompting the researchers to test whether interfering with the pathway could make a difference.
These results should be seen as a description of possible pathways, not a complete account of everything alcohol does. Two changes occurring together do not automatically prove that one is the sole cause of the other, and immune responses involve many interacting cells and signals. Still, the fact that cellular and molecular shifts appeared alongside a weaker treatment response gives researchers specific leads to test in future experiments, rather than leaving them with only the observation that treatment outcomes vary among individuals.
Blocking TIGIT Restored Part of the Response
The researchers tested whether intervening in some of the changes they had identified could improve the response to anti-PD-1 treatment. When they used antibodies to block TIGIT, the animals’ response to PD-1 treatment improved again. This finding is important because it links an alternative immune signal to an outcome that could be altered in the experimental model. The team did not merely observe that TIGIT levels had risen; it also tested whether blocking the receptor changed the course of the response.
The team also tried inhibiting SREBP signaling with a compound called betulin. This intervention improved the treatment’s effect, but less than blocking TIGIT did. The comparison suggests that the two approaches did not improve treatment equally in these experiments. It is not enough, however, to identify the better treatment for people or to recommend using either compound in a clinic. The findings come from animal experiments, and any move toward human treatment would require separate clinical trials to assess both effectiveness and safety.
The experiment also shows how understanding a mechanism could open the door to testing combination strategies, such as pairing a PD-1-targeting treatment with an intervention that limits another immune checkpoint pathway. That remains a research possibility, not evidence that adding a TIGIT blocker or betulin would help patients who drink alcohol. The distinction is important: a successful intervention in mice provides preliminary evidence worth following up, but it does not establish the right dose, benefits, or risks in people.
What Did the Patient Data Show?
Alongside the mouse experiments, the team conducted a retrospective analysis of patients with skin, lung, bladder, and head and neck cancers who had received immune checkpoint inhibitors. The researchers compared survival after treatment began according to patients’ reports of their alcohol consumption. Reporting eight or more drinks per week was associated with poorer survival after treatment started.
The relationship appeared clearest in lung cancer: regular drinking was associated with a smaller survival benefit from immunotherapy among these patients. The findings were less conclusive for the other cancers in the analysis because the available information about alcohol use was insufficient. The results should not be taken to show that drinking has the same effect in skin, bladder, and head and neck cancers, or that the same pattern applies to every patient receiving treatment.
Because the patient analysis was retrospective, it examined records that had already been collected; participants were not randomly assigned to groups according to their drinking habits. Alcohol consumption was based on what people reported about themselves, so the accuracy of the classification depended on how complete and reliable those reports were. Other factors could also have influenced survival or the recording of alcohol use. The results therefore support an association worth investigating, but do not prove that alcohol alone caused the observed difference or establish exactly how much it affects any particular group.
What the Study Still Cannot Settle
The study brings together two kinds of evidence that complement each other, but each has limitations. Mouse models allow researchers to control ethanol exposure, monitor changes inside tumors, and test specific interventions. But they cannot represent every aspect of human disease and treatment. Patient data bring the question closer to clinical reality, but the retrospective design and limited reports of drinking in some cancer groups make it harder to draw firm conclusions about cause and effect.
The description of exposure in the experiments as moderate to high does not provide a precise dose that can be directly matched to a particular drinking pattern in people. The most prominent figure from the human data is the threshold of eight drinks per week, as reported by patients—not a standardized dose given to everyone in the study. The two figures should not be combined or treated as equivalent measures. Nor does the study provide a way to predict an individual patient’s treatment outcome based only on how much they drink.
Important questions remain open. Would the same association appear in larger groups? Does it vary by tumor type, treatment, or patient characteristics? How clinically important is each observed immune change? The available evidence does not provide definitive answers. It does, however, show why recording alcohol use more clearly in cancer databases could be useful. With more complete information, researchers could compare outcomes across treatments and patient groups instead of relying on missing or difficult-to-compare data.
A Next Step Toward More Complete Treatment Data
The study’s authors argue that including information about alcohol use in cancer patient databases could help clarify its relationship with outcomes across different treatments. They highlighted CAR T-cell therapy—short for chimeric antigen receptor T-cell therapy—as well as chemotherapy and radiation therapy as areas for further investigation. The point is not that the study has shown alcohol weakens these treatments too. Rather, collecting broader data could allow researchers to ask and test that question across different cancers and therapies.
Researchers at the University of North Carolina at Chapel Hill conducted the study, which was published in Science Signaling as an article on how alcohol use affects anti-PD-1 treatment and disrupts antitumor immunity. The authors described their work as an initial resource for understanding the potential risks of regular drinking during immune checkpoint treatment and identifying mechanisms that could be investigated as possible intervention targets. That framing reflects the study’s exploratory nature: it offers biological clues and clinical associations, and calls for systematic follow-up rather than presenting the issue as settled.
From a research perspective, using a consistent method to ask about and record alcohol consumption could make studies easier to compare, especially when some findings are less clear because reports are incomplete. Linking exposure data with treatment outcomes, cancer type, and the treatment used could help determine whether the relationship is limited to certain groups or is more widespread. The purpose of these steps is not to prove a predetermined idea, but to provide better data for evaluating it—including the possibility that the effect may not be the same in every setting.
The Bottom Line
The study outlines one possible way regular drinking could be linked to a weaker response to anti-PD-1 immunotherapy. In mouse models of lung and bladder cancer, ethanol reduced treatment effectiveness by about 50% and coincided with more tumor recurrence, as well as changes in immune cells and their signals. Blocking TIGIT improved the response in mice, while inhibiting SREBP with betulin had a smaller effect. In the patient analysis, drinking eight or more drinks a week was associated with poorer survival, with the clearest signal in lung cancer. But the patient data cannot prove that alcohol caused the difference, and animal experiments cannot support a treatment recommendation. More complete clinical data and larger studies are needed to find out how well these results apply to people and to different cancers and treatments.